Leukoencephalopathy in patients with brain metastases who received radiosurgery with or without whole brain radiotherapy

Background Whole brain radiation therapy (WBRT) for brain metastases (BMs) is a common cause of radiation-induced leukoencephalopathy; however the safety of alternative stereotactic radiosurgery (SRS) remains unclear. This study examined the incidence of leukoencephalopathy in patients treated with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2023, Vol.161 (1), p.85-95
Hauptverfasser: Liu, Chan-Wei, Yang, Huai-Che, Chiang, Chi-Lu, Shen, Chia-I., Wu, Hsiu-Mei, Luo, Yung-Hung, Hu, Yong-Sin, Lin, Chung-Jung, Chung, Wen-Yuh, Shiau, Cheng-Ying, Guo, Wan-Yuo, Pan, David Hung-Chi, Lee, Cheng-Chia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Whole brain radiation therapy (WBRT) for brain metastases (BMs) is a common cause of radiation-induced leukoencephalopathy; however the safety of alternative stereotactic radiosurgery (SRS) remains unclear. This study examined the incidence of leukoencephalopathy in patients treated with SRS alone versus WBRT plus SRS for BMs with a focus on the relationship between prognostic factors and leukoencephalopathy. Methods Analysis was performed between 2002 and 2021. The total enrollment was 993 patients with the distribution: WBRT plus SRS (n = 291) and SRS only (n = 702). Leukoencephalopathy was graded from 0 to 3 for changes in white matter indicated by the MRI after WBRT or SRS. Patient characteristics and SRS dosimetric parameters were reviewed to identify factors that contributed to the incidence of leukoencephalopathy or overall survival. Results The incidence of leukoencephalopathy was consistently higher in WBRT plus SRS group than in SRS alone group (p  77 years; p = 0.025). Nonetheless, the SRS integral dose to skull in the subgroup of WBRT plus SRS treatment was not demonstrated significance in development of leukoencephalopathy (p = 0.986 for integral dose 1–2 J, p = 0.776 for integral dose > 2 J). Conclusions This study revealed that SRS is safe for oligo-BMs in terms of leukoencephalopathy development. Patient age and total tumor volume were identified as important factors in assessing the development of leukoencephalopathy. The additional of SRS (even at an integral dose > 2 J) did not increase the incidence of leukoencephalopathy.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-022-04210-5